A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.

医学 抗体-药物偶联物 耐受性 曲妥珠单抗 帕妥珠单抗 曲妥珠单抗 肿瘤科 内科学 癌症研究 抗体 药理学 癌症 乳腺癌 不利影响 单克隆抗体 免疫学
作者
Sara A. Hurvitz,Erika Hamilton,Alexander I. Spira,Paula R. Pohlmann,Antonio Giordano,Katherine Clifton,Barry Anderson,Sujoy Dutta,Umesh Mangipudi,Shikha Saini,James Palacino,Tina Karunaratne,Dennise Greensmith,Olaf Christensen,Sharon Wilks
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (16_suppl): TPS1114-TPS1114 被引量:15
标识
DOI:10.1200/jco.2023.41.16_suppl.tps1114
摘要

TPS1114 Background: Targeted protein degradation (TPD) molecules have expanded the therapeutic options through their catalytic mechanism of action (MOA) and ability to degrade “undruggable” proteins. To increase the efficacy versus tolerability window of protein degradation and improve drug delivery, ORM-5029 uses a Dual-Precision TPD (TPD 2 ) approach combining the catalytic mechanism of TPDs with the precision of tumor-targeting therapeutic antibodies. ORM-5029 is a first-in-class human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) comprised of SMol006, a highly potent GSPT1 degrader, conjugated to pertuzumab, a clinically validated antibody. HER2 is overexpressed in cancers such as breast, ovarian and gastric, and associated with early-onset aggressive disease. ORM-5029 is in development for treatment of HER2-expressing solid tumors. The MOA is mediated by targeted uptake of the ADC, release of the TPD payload, and cell death by GSPT1 degradation. ORM-5029 showed robust in vitro and in vivo efficacy in multiple HER2-expressing models with comparable activity to trastuzumab deruxtecan and strong activity in trastuzumab emtansine-refractory models. Methods: This phase 1 first-in-human study evaluates the safety, tolerability, and efficacy of ORM-5029 administered by intravenous infusion in patients (pts) with HER2-expressing advanced solid tumors (NCT05511844). The escalation, guided by the Bayesian Optimal Interval design, explores cohorts of ORM-5029 to identify the maximum tolerated dose (MTD) and/or expansion dose level (EDL). Each cohort will enroll ≥3 breast cancer pts with at least HER2 1+ (HER2 low) or greater by immunohistochemistry or positive by in situ hybridization. Expansion cohort A (HER2+ breast cancer) may enroll in parallel to escalation evaluating doses showing pharmacodynamic activity or efficacy. Up to 10 pts may be enrolled at each dose explored in cohort A. Enrollment into expansion cohort B (up to 21 pts) and cohort C (up to 22 pts) will begin once the EDL has been determined to further assess the safety, tolerability and efficacy of ORM-5029 using a Simon’s optimal 2-stage design. Cohort B will enroll pts with HER2+ breast cancer refractory or intolerant to standard treatment after ≥2 HER2 therapies in the metastatic setting. Cohort C will enroll pts with advanced solid tumors that are refractory or intolerable to standard treatment or for which no standard treatment is available, including HER2+ gastric or gastroesophageal junction adenocarcinoma or tumors with HER2 expression, amplification or mutations (e.g., colorectal, bile duct, ovarian, bladder, non-small cell lung). Study enrollment began in October 2022 in the United States. Escalation cohort 1 was completed without DLT; enrollment in cohort 2 began as of December 2022. Clinical trial information: NCT05511844 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
十二十三完成签到 ,获得积分10
1秒前
ybk666完成签到,获得积分10
1秒前
grh发布了新的文献求助10
1秒前
慕念完成签到,获得积分10
2秒前
爆米花的应助被魔术师采纳,获得10
2秒前
科目三的应助被咕咕day采纳,获得10
3秒前
eve完成签到,获得积分20
4秒前
华仔的应助被初温采纳,获得10
5秒前
5秒前
在水一方的应助被sunidea采纳,获得10
5秒前
6秒前
moon完成签到,获得积分10
6秒前
anian发布了新的文献求助10
6秒前
科研通AI6.2的应助被Zzz采纳,获得10
8秒前
Mu完成签到,获得积分10
8秒前
迷途书童完成签到,获得积分10
9秒前
情怀的应助被阔达莺采纳,获得10
9秒前
10秒前
10秒前
畅快皮皮虾完成签到 ,获得积分10
11秒前
Kia发布了新的文献求助10
12秒前
zuol发布了新的文献求助10
12秒前
wkk关闭了wkk的文献求助
13秒前
13秒前
玔堷完成签到,获得积分0
13秒前
ding的应助被淡然的尔云采纳,获得10
14秒前
斯文败类的应助被老爷采纳,获得10
14秒前
14秒前
14秒前
LiangKeCheng完成签到,获得积分10
15秒前
梦云归完成签到,获得积分10
15秒前
小丁完成签到,获得积分10
15秒前
濮阳冰海完成签到 ,获得积分10
15秒前
molihuakai的应助被yimuyi采纳,获得10
16秒前
16秒前
16秒前
开朗熊猫完成签到,获得积分10
16秒前
16秒前
M.pang完成签到,获得积分10
16秒前
小小的白发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160632
求助须知:如何正确求助?哪些是违规求助? 9555512
关于积分的说明 21728801
捐赠科研通 7750444
什么是DOI,文献DOI怎么找? 3427429
关于科研通互助平台的介绍 2552456
邀请新用户注册赠送积分活动 2471817